Business Wire

RMS Enables Organizations to “Flatten the Curve” From Acute and Chronic Disasters With Modern Risk Technology

Share

The world is experiencing the extraordinary crisis of the COVID-19 pandemic, coupled with the never-ending climate crisis and escalating cyber threats. Markets, supply chains, economies, societies and assets can be highly susceptible to shocks and damage from these dynamically shifting risks, posing major challenges to understanding the impacts of these risks and to recovery. Today, at the annual Exceedance® conference, RMS, the world’s leading catastrophe risk solutions company, underscored the high cost that both acute and chronic risks pose while demonstrating that informed decision-making requires next-generation risk insights. To help address these challenges, RMS announced new model updates during the conference – focusing on infectious diseases, climate and cyber risk.

During his keynote presentation today, Mohsen Rahnama, Executive Vice President, Models, at RMS, compared lessons from COVID-19 to the response to climate change: “Over the last 120 days, every daily action has been critical to flattening the COVID-19 curve and has given us more data to gain insights into outcomes; similarly, climate change has gradually influenced risk over the last 120 years and will for the years to come. In turn, actions taken annually by companies and organizations will be equally critical to both understanding the totality of the risks and impacting outcomes. The effects span all parts of the insurance value chain from acute risks arising from catastrophic events, such as hurricane landfalls, to chronic risks, such as coastal flooding at high tide.”

In the same keynote, Pete Dailey, Vice President, Model Development, at RMS, stressed that science, data and models have together brought higher confidence to the relationship between climate change and insured perils. “One example is sea level, which we know, based on observations and physics, is rising globally and will continue to rise in the future. RMS is moving forward on two fronts: first, keeping cat models up to date with the latest in climate science, and second, developing new ways of projecting risk based on the future climate, in the near term as well as the long term. In addition, due to COVID-19, extreme weather events that occur this year, such as a major hurricane landfall, will potentially present a number of new challenges for insurers, such as with deployment of adjusters and claims processing, potentially while communities are social distancing. RMS Event Response services provide critical real-time insights for these types of events to help meet these challenges.”

Companies and governments are compelled to understand risks more deeply than ever before, and they need modern technology and the highest-quality, most-advanced models to accomplish this challenging task.

RMS has recently enhanced key models to help clients address the risks posed by these chronic and acute disasters.

  • RMS Infectious Diseases Model
    The RMS Infectious Diseases Model (IDM) provides a probabilistic view of loss that could result from a full range of infectious disease pandemics, including COVID-19, and epidemics ranging from influenza to Ebola. Updated most recently in the RMS LifeRisks® platform Version 2.7, the model captures the impact of infectious diseases on mortality and morbidity for multiple age groups in 59 different countries, and it considers the use of non-pharmaceutical interventions used to slow transmission throughout a population. Recent model updates capture improvements in global vaccine production and manufacturing capacity, the availability and efficacy of pharmaceuticals, country-specific pandemic response and the underlying health of an insured portfolio, leading to a better understanding of how different factors impact pandemic mortality. To assess the dynamic impact of the COVID-19 pandemic, RMS also offers projections on the number of cases, deaths and hospitalizations by region, accounting for regional mitigation measures. Clients can understand the expected impact of COVID-19 over a multi-month time horizon and get updated forecasts based on risk and response developments over time.
  • RMS Climate Models
    RMS offers robust analytics through a global suite of climate models for hurricane/typhoon, extratropical cyclone, flood, severe convective storm, winter storm and wildfire. Built on consensus science and recent empirical data, RMS models incorporate the most important aspects and recent observations around climate change to ensure a stable and dependable view of risk. New advancements with RMS Risk Intelligence™ and Risk Modeler™ 2.0 offer even greater flexibility and computational power for RMS models. Clients can analyze their book of business to measure current climate impacts including consensus trends due to climate change, leveraging either Risk Modeler 2.0 starting June 2020, their current RiskLink ® solution or RMS Analytical Services. The results inform both expected and tail risks. The Europe Severe Convective Storm High Definition Models are the newest climate models to be added to the global climate model suite and are available through RMS Analytical Services now and on Risk Modeler 2.0 this summer.
  • RMS Cyber Solutions
    Initially released in February 2016 in collaboration with the Cambridge Centre for Risk Studies and eight insurance partners, the RMS cyber model has been well received in the insurance market. The very dynamic nature of cyber risk has translated to significant and regular annual improvements in the model since its very first release, most recently with the release of Cyber Solutions Version 4.0 in October 2019. Enhancements in Version 4.0 included exposure data enrichment, new hazard data, a cyber loss module and computation enhancements. RMS continues this trajectory and is making further enhancements in 2020 in its next release, Cyber Solutions version 4.1, along with a brand new Cyber Underwriting capability, that includes rich new dashboards for simplified underwriting, which will be available by September 2020.

ENDS

Related Announcements:

About RMS

Risk Management Solutions, Inc. (RMS) helps insurers, financial markets, corporations, and public agencies evaluate and manage global risk from natural and man-made catastrophes, including hurricanes, earthquakes, floods, climate change, cyber and pandemics.

RMS leads the catastrophe risk industry that we helped to pioneer by marrying data and advanced model science with leading-edge technology. Leaders across multiple industries can address the risks of tomorrow through RMS Risk Intelligence, our open, real-time exposure and risk management platform, enabling them to tap into RMS HD Models™, rich data layers, intuitive applications and APIs that simply integrate into existing enterprise systems.

RMS is a trusted solutions partner enabling effective risk management for better business decision-making across underwriting, risk selection, mitigation and portfolio management.

Visit RMS.com to learn more and follow us on LinkedIn and Twitter.

© 2020 Risk Management Solutions, Inc. RMS, the RMS logo, and all other identified marks are trademarks of Risk Management Solutions, Inc. All other trademarks may be claimed as the property of others.

Contact information

Matthew Longbottom (U.K.)
+44 (0) 7584 333485
prteam@rms.com

Devonne Cusi (U.S.)
+1 551 226 1604
prteam@rms.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom